Balaxi Pharma

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 09-Aug, Balaxi Pharmaceuticals Ltd's stock price is rising to 24.32, reflecting a 0.5% increase today and positive short-term performance. However, it has faced significant long-term declines, including a 9.49% drop year-to-date and a 72.70% decline over three years, indicating potential long-term challenges despite current upward trends.

As of 09-Aug, Balaxi Pharmaceuticals Ltd's stock price is rising, currently at 24.32, with a change of 0.12 (0.5%) upwards. This increase can be attributed to its performance today, where it outperformed the sector by 2.52%. Additionally, the stock has shown positive returns over the past week and month, with increases of 1.76% and 1.97%, respectively, while the benchmark Sensex has shown lower gains during the same periods. <BR><BR>However, it is important to note that despite today's rise, the stock has experienced significant declines over longer periods, including a year-to-date drop of 9.49% and a staggering 72.70% decline over the past three years. The stock is currently trading above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short-term upward trend, although it remains below the 200-day moving average, suggesting potential long-term challenges. <BR><BR>Investor participation has decreased, as evidenced by a decline in delivery volume by 11.11% against the 5-day average, which may indicate caution among investors. Nonetheless, the stock's liquidity remains adequate for trading. Overall, the current rise in Balaxi Pharmaceuticals Ltd's stock price appears to be driven by short-term performance metrics, despite the backdrop of longer-term declines.

Which are the latest news on Balaxi Pharma?

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

Balaxi Pharmaceuticals Ltd's latest results show a significant net profit increase of 348.28% and 14.05% revenue growth, but ongoing challenges with profitability and a 48.79% stock decline over the past year suggest caution for investors. The company's high valuation and low advisory score indicate skepticism about its future prospects.

Balaxi Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-over-year increase in net profit of 348.28% for Q1 FY27, reaching ₹1.30 crore, and a revenue growth of 14.05%, which is a positive sign. The operating profit margin, however, remains under pressure at 5.78%, indicating challenges in translating revenue growth into sustainable profitability.<BR><BR>Despite these improvements, the overall context is concerning. The stock has seen a dramatic decline of 48.79% over the past year, and it currently trades at a high price-to-earnings ratio of 94 times, which raises questions about its valuation relative to its financial performance. The company has also faced deteriorating profitability metrics and a negative long-term growth trajectory, with a five-year EBIT CAGR of -27.00%.<BR><BR>Investor sentiment appears to be cautious, as reflected by the company's low advisory score of 21 out of 100, indicating a "Strong Sell" recommendation. Additionally, there has been a significant exit of institutional investors, which further underscores the skepticism surrounding the company's future prospects.<BR><BR>In summary, while there are signs of recovery in the latest quarter, the broader financial challenges and market sentiment suggest that investors should approach Balaxi Pharmaceuticals with caution.

Should I buy, sell or hold Balaxi Pharmaceuticals Ltd?

How big is Balaxi Pharma?

As of 10th June, Balaxi Pharmaceuticals Ltd has a market capitalization of 133.00 Cr, with recent net sales of 270.17 Cr and a net profit of 1.42 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Balaxi Pharmaceuticals Ltd has a market capitalization of 133.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 270.17 Cr, while the sum of Net Profit for the same period is 1.42 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual period reported is March 2025, with Shareholder's Funds amounting to 231.74 Cr and Total Assets of 310.34 Cr.

Who are in the management team of Balaxi Pharma?

The management team of Balaxi Pharma includes Ashish Maheshwari (Chairman/Executive Director), Minoshi Maheshwari (Non Executive Director), and five Independent Non Executive Directors: Kunal M Bhakta, Gandhi Gamji, M. Srinivas Rao, and Purnima Singh Kamble.

The management team of Balaxi Pharma includes the following members:<BR><BR>1. **Ashish Maheshwari** - Chairman / Executive Director<BR>2. **Minoshi Maheshwari** - Non Executive Director<BR>3. **Kunal M Bhakta** - Independent Non Executive Director<BR>4. **Gandhi Gamji** - Independent Non Executive Director<BR>5. **M. Srinivas Rao** - Independent Non Executive Director<BR>6. **Purnima Singh Kamble** - Independent Non Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Balaxi Pharma?

Balaxi Pharma's peers include Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Smruthi Organic, Godavari Drugs, and Concord Drugs. Balaxi Pharma has a low 1-year return of -56.08%, while Lactose (India) leads with a return of 0.00%.

Peers: The peers of Balaxi Pharma are Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Smruthi Organic, Godavari Drugs, and Concord Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alpa Laboratorie and Denis Chem Lab, while Average management risk is found at Bal Pharma, Balaxi Pharma, Smruthi Organic, Godavari Drugs, and Tyche Industries. Below Average management risk is noted at Sotac Pharma, Lactose (India), and Concord Drugs. Growth is Excellent at Lactose (India), Below Average at Alpa Laboratorie, Bal Pharma, Balaxi Pharma, Smruthi Organic, Godavari Drugs, and Tyche Industries, and does not qualify for Krebs Biochem. Capital Structure is Excellent at Alpa Laboratorie and Balaxi Pharma, Good at Smruthi Organic, and Below Average at Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Godavari Drugs, and Concord Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lactose (India) at 0.00%, while Balaxi Pharma has the lowest at -56.08%, indicating a significantly poorer performance compared to its peers. Additionally, Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, and Godavari Drugs all have negative six-month returns.

What does Balaxi Pharma do?

Balaxi Pharmaceuticals Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reported net sales of 71 Cr and a net profit of 1 Cr for March 2026. The company, originally incorporated in 1942, focuses on pharmaceutical products and has a market cap of INR 133 Cr.

Overview: <BR>Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1942 under the name 'The Anandam Rubber Company Limited' and changed its name to 'Balaxi Ventures Limited' in 2017. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 71 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 95.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 0.57% <BR>Price to Book: 0.54<BR><BR>Contact Details: <BR>Address: 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road Cochin Kerala : 682035 <BR>Tel: 91-484-4032952/6596725 <BR>Email: secretarial@anandamrubberco.com <BR>Website: http://www.balaxipharma.in

Is Balaxi Pharma overvalued or undervalued?

As of November 27, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 14.36, significantly lower than its peers like Bajaj Finance and Bajaj Finserv, despite a 53.22% decline in stock performance over the past year.

As of 27 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.36, an EV to EBIT of 11.30, and an EV to EBITDA of 10.33. These ratios suggest that Balaxi Pharma is trading at a lower valuation compared to its peers, particularly when compared to Bajaj Finance, which has a PE ratio of 35.15, and Bajaj Finserv, with a PE ratio of 34.78.<BR><BR>In the context of its industry, Balaxi Pharma's Price to Book Value stands at 0.87, which further reinforces its undervaluation relative to competitors like Life Insurance, which has a PE ratio of 11.14 and an EV to EBITDA of 9.18. Despite recent stock performance showing a decline of 53.22% over the past year compared to a 7.99% increase in the Sensex, the current valuation metrics position Balaxi Pharma as an attractive investment opportunity moving forward.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024. The company's total assets increased to 310.34 Cr in March 2025, up from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr from 258.34 Cr. Cash flow from operating activities turned negative at -35.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2024, indicating challenges in cash generation. Overall, Balaxi Pharma's financial performance reflects volatility with a recent trend of declining profits despite increased sales.

Who are the top shareholders of the Balaxi Pharma?

The top shareholders of Balaxi Pharma include Balaxi Overseas Private Limited with 63.4%, foreign institutional investors holding 16.02%, and Unico Global Opportunities Fund Limited as the largest public shareholder at 8.29%. Individual investors own 9.82%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Balaxi Pharma include the promoters, with Balaxi Overseas Private Limited holding the largest share at 63.4%. Additionally, foreign institutional investors (FIIs) collectively hold 16.02%, with three FIIs involved. The highest public shareholder is Unico Global Opportunities Fund Limited, which owns 8.29%. Individual investors account for 9.82% of the company's shares. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

What is the technical trend for Balaxi Pharma?

As of April 21, 2025, Balaxi Pharma's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and KST indicators, despite some divergence in the RSI and mildly bearish Bollinger Bands.

As of 21 April 2025, the technical trend for Balaxi Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, indicating some divergence. Bollinger Bands are mildly bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. Overall, the bearish signals dominate the current technical outlook.

When is the next results date for Balaxi Pharma?

No Upcoming Board Meetings

Has Balaxi Pharma declared dividend?

Balaxi Pharmaceuticals Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of July 1, 2022. Despite this, the company has experienced significant volatility, showing negative total returns in shorter periods, while the 5-year period reflects a positive return of 138.34%.

Balaxi Pharmaceuticals Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 01 Jul 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -38.66%, the dividend return was 0%, resulting in a total return of -38.66%.<BR><BR>For the 1-year period, the price return was -51.55%, the dividend return was 0%, leading to a total return of -51.55%.<BR><BR>Over the 2-year period, the price return was -51.61%, with a dividend return of 0%, culminating in a total return of -51.61%.<BR><BR>In the 3-year period, the price return was -37.85%, the dividend return was 0.68%, resulting in a total return of -37.17%.<BR><BR>For the 4-year period, the price return was -57.93%, the dividend return was 0.43%, leading to a total return of -57.5%.<BR><BR>In the 5-year period, the price return was 136.37%, with a dividend return of 1.97%, culminating in a total return of 138.34%.<BR><BR>Overall, Balaxi Pharmaceuticals Ltd has declared a dividend, but the total returns over the various periods indicate significant volatility, with negative returns dominating in the shorter time frames, while the 5-year period shows a substantial positive return.